Barinthus Biotherapeutics PLC
NASDAQ:BRNS

Watchlist Manager
Barinthus Biotherapeutics PLC Logo
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Watchlist
Price: 0.7028 USD -2.56% Market Closed
Market Cap: 28.7m USD

Barinthus Biotherapeutics PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Barinthus Biotherapeutics PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
EPS (Diluted)
-$1
CAGR 3-Years
-4%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
EPS (Diluted)
-$2
CAGR 3-Years
26%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
EPS (Diluted)
-$3
CAGR 3-Years
-2%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
EPS (Diluted)
-£1
CAGR 3-Years
31%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
EPS (Diluted)
£0
CAGR 3-Years
-23%
CAGR 5-Years
-12%
CAGR 10-Years
-8%
Oxford BioMedica PLC
LSE:OXB
EPS (Diluted)
£0
CAGR 3-Years
-10%
CAGR 5-Years
-17%
CAGR 10-Years
-6%
No Stocks Found

Barinthus Biotherapeutics PLC
Glance View

Market Cap
28.7m USD
Industry
Biotechnology

Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

BRNS Intrinsic Value
Not Available

See Also

What is Barinthus Biotherapeutics PLC's EPS (Diluted)?
EPS (Diluted)
-1.6 USD

Based on the financial report for Dec 31, 2024, Barinthus Biotherapeutics PLC's EPS (Diluted) amounts to -1.6 USD.

What is Barinthus Biotherapeutics PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-21%

Over the last year, the EPS (Diluted) growth was 19%. The average annual EPS (Diluted) growth rates for Barinthus Biotherapeutics PLC have been -4% over the past three years , -21% over the past five years .

Back to Top